Chemexpress(SH:688131) Zheng Quan Ri Bao Wang·2025-12-15 13:15Core Viewpoint - The company, Haoyuan Pharmaceutical, emphasizes its commitment to a development strategy focused on "industrialization, globalization, and branding," aiming for steady growth across its three main business engines [1] Group 1: Business Development - The revenue from the ADC (Antibody-Drug Conjugate) business currently constitutes a significant portion of the revenue from the backend innovative drug CDMO (Contract Development and Manufacturing Organization) [1] - The company has established a strong competitive advantage in the ADC small molecule sector, with the successful operation of its Chongqing ADC CDMO base in March marking the formation of a comprehensive service system across Shanghai, Ma'anshan, and Chongqing [1] - Haoyuan has developed into a rare one-stop ADCCDMO enterprise in China, offering a full-chain closed-loop service capability that includes Payload-Linker development, antibody discovery, conjugation process optimization, and commercial production [1] Group 2: Market Expansion and Strategy - The company is actively promoting market outreach and project advancement in Chongqing, with a rapid increase in new signed orders [1] - A strategic investment department has been established, and the company does not rule out the possibility of expanding its international market presence through mergers, acquisitions, and partnerships [1] - The company has no undisclosed information that needs to be revealed, and any significant investment or acquisition plans will be communicated through relevant announcements [1]